Triple attack on prostate cancer: drug, surgery, and radiation aim to stop spread
NCT ID NCT07490210
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding surgery and targeted radiation to a new hormone-blocking drug (rezvilutamide) can help men whose prostate cancer has spread to a few spots (oligometastatic). 300 men will be split into three groups: one gets the drug alone, one gets drug plus surgery, and one gets drug plus surgery plus radiation. The goal is to see which approach best delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rezvilutamide (a hormone-blocking drug) plus androgen deprivation therapy (ADT)
What this could lead to
If successful, this combination approach could offer a way to delay cancer progression and improve survival for men with prostate cancer that has spread to a few spots.
What could go wrong
This is an early Phase 2 trial, so results are not yet proven. The added treatments (surgery and radiation) carry risks like side effects from surgery or radiation, and the drug may cause fatigue, hot flashes, or other hormone-related issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••